Aesthetic Medical International Holdings Group Ltd.

Good morning, ladies and gentlemen, and thank you for standing by, and welcome to Aesthetic Medical International second quarter and first half of 2021 earnings conference call. During today's presentation, all parties will be in a listen-only mode. As a reminder, today's conference call is being recorded. On the call today from Aesthetic Medical International are Dr. Pang Wu-Jiao, Chairman and Chief Executive Officer, Mr. Toby Wu, Chief Financial Officer, Mr. Joe Tzu, Senior Director of Investment Relations and Mr. Derek Shih, Assistant to Chairman. Dr. Joe will review the business operations and the company's highlights, followed by Mr. Joe Chu, who will introduce the company's financial performance. Chairman's CFO and IR team will all be available to answer your questions during the Q&A session that follows. Before we get started, I would like to remind you that some of the information discussed will include forward-looking statements regarding future events and our future financial performance. These include statements about our future expectations, financial projections, and our plans and prospects. Actual results may differ materially from those set forth in such statements. For discussion of these risks and uncertainties, you should review the company's filings with the SEC, which includes today's press releases. you should not rely on our forward-looking statements as predictions of future events. All forward-looking statements that we make on this call are based on assumptions and beliefs as of today, and we undertake no obligation to update them except as required by applicable law. Our discussion today will include non-IFRS financial measures, including EBITDA, adjusted loss, and adjusted EBITDA. You should not consider EBITDA adjusted EBITDA and adjusted loss as a substitute for or superior to net income prepared in accordance with IFRS. Furthermore, because non-IFRS measures are not prepared in accordance with IFRS, they are susceptible to varying calculations and may not be comparable to other similarly titled measures presented by other companies. You are encouraged to review the company's financial information in its entirety and and not rely on a single financial measure. At this time, I would like to turn the call over to Dr. Peng Ruizhou, Chairman and CEO of Aesthetic Medical International. His opening remarks will be delivered in English by his assistant, Mr. Derek Shi. Dr. Ju, Dr. Ju, please go ahead.

Thank you, host. Thank you all for attending today's meeting. I am very happy to announce that this week's The company's operation and financial performance have regrouped strategically, and its development in the medical field has also achieved impressive results. As the COVID-19 pandemic gradually subsided, residents have resumed their daily activities, and the consumption of medical services has benefited from the resumption of market demand. Our active customers increased by 21.7% in the first half of 2021 and increased by 68.6% and 8.4% in the second half of 2021. After adjustment,

Thank you, operator, and everyone for joining the call today. We are pleased to see an encouraging result in this quarter in terms of operational and financial results, strategic restructuring plans, and our development in the field of non-surgical aesthetic medical services. As the impact of COVID-19 has been gradually receding in mainland China, the public has resumed their daily activities as well as their consumption of aesthetic medical services. Supported by the recovery of market demand, the number of our active customers in the first half of 2021 increased by 21.7% year over year, which drove the revenue growth of 68.6% year over year, and a gross profit margin improvement of 8.4 percentage points in the first half of 2021. Adjusted EBITDA also rebounded from loss in the first half of 2020 to profit in the first half of 2021.